Apabetalone

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Retrieved on: 
Friday, September 30, 2022
Human body, VP, Safety, Infection, TSX, COVID-19, Risk, FDA, Virus, Feedback, Conditional sentence, Suggestion, Senior, News, Industry, Apabetalone, End organ damage, BD2, PCC, Patient, Cell, Vaccination, CDC, BET, Post, US Foods, GLOBE, Awareness, HIV disease progression rates, Drug, Pharmaceutical industry

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalones future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalones future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter Resverlogix in the search box.
  • A recent estimate from the CDC suggests that as many as one-in-three US adults may experience long-COVID after contracting COVID-19.
  • Resverlogix has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format.

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Retrieved on: 
Wednesday, September 28, 2022
Human body, Safety, Infection, TSX, COVID-19, Risk, FDA, Apabetalone, Food, Virus, Feedback, Conditional sentence, Legislation, Nature, Intention, Company, Senior, News, Breakthrough therapy, Industry, End organ damage, BD2, PCC, Patient, Cell, Vaccination, CDC, Centers for Disease Control and Prevention, Cardiovascular disease, BET, Post, Use-centered design, US Food Sovereignty Alliance, GLOBE, SEDAR, Drug, Disease, Pharmaceutical industry, Vaccine, Medical device

There are currently few available treatment options for this group of people, and we feel that apabetalone has great potential to help them.

Key Points: 
  • There are currently few available treatment options for this group of people, and we feel that apabetalone has great potential to help them.
  • The investigational treatment could potentially reduce the severity and duration of post COVID-19 conditions.
  • Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes.
  • The Companys clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and COVID-19.

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Retrieved on: 
Monday, August 22, 2022
Cardiovascular disease, Cardiology, COVID-19, Conditional sentence, Non-alcoholic fatty liver disease, Safety, Cell, Legislation, Breakthrough therapy, Risk, HHF, Moderate, Disease, US Foods, FS, Virus, Food, BD2, BET, TSX, GLOBE, Intention, Â, Cirrhosis, Company, FDA, Bromodomain, American Journal, News, Type 2 diabetes, MACE, SEDAR, Industry, Human body, European Journal of Preventive Cardiology, Acute coronary syndrome, End organ damage, Nature, Pharmaceutical industry, Dietary supplement, Medical device, Apabetalone, Patient

The article presents a post-hoc analysis of BETonMACE data, which demonstrates apabetalone treatment improves cardiac outcomes and liver fibrosis scores in patients with moderate-to-high likelihood of advanced liver fibrosis.

Key Points: 
  • The article presents a post-hoc analysis of BETonMACE data, which demonstrates apabetalone treatment improves cardiac outcomes and liver fibrosis scores in patients with moderate-to-high likelihood of advanced liver fibrosis.
  • These promising findings make the case for a larger study of non-alcoholic fatty liver disease patients to better understand the scope of apabetalones benefit.
  • It is a BD2 (bromodomain) selective BET (bromodomain andextra-terminal) inhibitorthat works in preventing and treating disease progression byregulating the expression of disease-causing genes.
  • Data from BETonMACE showed apabetalone can potentially prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Retrieved on: 
Wednesday, June 8, 2022
Conditional sentence, BD2, Apabetalone, Chromatin, Company, Research, Cell, US Foods, Cell death, Food, Legislation, BRD4, Nature, News, Beti, Disease, Inflammation, Senior, End organ damage, Breakthrough therapy, Fabry disease, BET, Cardiovascular disease, FDA, GLOBE, Patient, TAD, Biomedicine & Pharmacotherapy, COVID-19, Risk, Research and development, TSX, Industry, Virus, Human body, Pharmacology, Intention, Safety, SEDAR, Online gambling, Pharmaceutical industry, Medical device, Fabry

The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-selective BET inhibitors.

Key Points: 
  • The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-selective BET inhibitors.
  • BD2-selective inhibitors, such as apabetalone, can inhibit the expression of disease-causing genes without disrupting the fundamental functions of cells.
  • The article details the beneficial impacts of apabetalone treatment on inflammatory pathways in immune cells from Fabry disease patients.
  • These findings suggest that apabetalone is a promising therapeutic candidate for the rare disorder.

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Retrieved on: 
Monday, May 9, 2022
Efficacy, Safety, TSX, Human body, Solution, High Risk, Breakthrough therapy, Risk, SEDAR, Twitter, Company, Heart failure, Patient, Infection, Partnership, Clinical trial, Potential, FDA, End organ damage, Industry, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hospital, Conditional sentence, LinkedIn, Intention, Disease, COVID-19, News, Research, Type, Albert Einstein College of Medicine, Stroke, Cell, Virus, University, Montefiore Medical Center, CORAL, BD2, GLOBE, Food, Cardiovascular disease, Legislation, BET, Organization, US Foods, History, Apabetalone, Health information management, Pharmaceutical industry, Medical device, Nature, Medicine

Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program.

Key Points: 
  • Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program.
  • Were pleased to support this important evolution of apabetalone and Resverlogix in its Phase 3 CORAL study, said Kevin McDermott, Resverlogix Chief Commercial Officer, EVERSANA.
  • The EVERSANA COMPLETE Commercialization model is built to support customer needs by offering flexibility to quickly adapt development and launch strategies to meet market demands.
  • Study site selection is currently underway, with sites expected in the United States, Canada, and the Middle East.

Resverlogix Announces One-Year Extension of Debenture

Retrieved on: 
Tuesday, April 19, 2022
News, CEO, Conditional sentence, BET, COVID-19, US Foods, Risk, Legislation, Apabetalone, Research, Intention, Food, BD2, GLOBE, Patient, Cell, End organ damage, Standard of care, Human body, Company, Breakthrough therapy, TSX, University, Partnership, FDA, Disease, Industry, SEDAR, Virus, Cardiovascular disease, Pharmaceutical industry, Medical device, Nature

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the Company) (TSX:RVX) announced today that it has closed a one-year extension of Companys US$6.0 million 10% secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink"), and payment of accrued interest thereon, extending the maturity date to May 13, 2023.

Key Points: 
  • CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the Company) (TSX:RVX) announced today that it has closed a one-year extension of Companys US$6.0 million 10% secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink"), and payment of accrued interest thereon, extending the maturity date to May 13, 2023.
  • It is a BD2 (bromodomain) selective BET (bromodomain andextra-terminal) inhibitorthat works in preventing and treating disease progression byregulating the expression of disease-causing genes.
  • Following a publication in Nature , authored by a consortium of top Universities and Research Institutions, on March 23, 2020, Resverlogix launched a COVID-19 program, conducting research internally and enlisting world-renowned collaborators.
  • Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes.

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Retrieved on: 
Thursday, March 17, 2022
Research, Education, Obesity, Human body, Conditional sentence, Standard of care, CEO, SEDAR, Legislation, Cardiovascular disease, COVID-19, Université Laval, PVR, Cardiology, BD2, Population, American Journal, TSX, Critical Care Medicine (journal), Risk, University, Cell, Patient, Health, Apabetalone, Science, Food, Volunteering, End organ damage, Disease, PAH, GLOBE, Intention, News, BET, FDA, Institute, US Food Sovereignty Alliance, Medicine, Company, Virus, Breakthrough therapy, Physician, Industry, Pulmonary hypertension, Pharmaceutical industry, Medical device, Nature

CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study in the prestigious American Journal of Respiratory and Critical Care Medicine which has an impact factor of 21.4.

Key Points: 
  • CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study in the prestigious American Journal of Respiratory and Critical Care Medicine which has an impact factor of 21.4.
  • The article outlines the positive impact of apabetalone in the investigator-led pulmonary arterial hypertension (PAH) pilot study, APPRoAcH-p.
  • We also want to recognize the important contribution of the IUCPQ Foundation to this work.
  • A Phase 2b clinical trial is evaluating apabetalone in combination with standard of care for patients hospitalized with COVID-19.

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

Retrieved on: 
Thursday, February 17, 2022
BET, Patient, Food, Biomarker, CEO, Legislation, Company, SEDAR, Cell, Health Canada, Safety, Standard of care, Risk, Intention, Human body, University, GLOBE, Virus, BD2, Conditional sentence, Cardiovascular disease, FDA, Hospital, End organ damage, US Food Sovereignty Alliance, Disease, Research, Inflammation, Breakthrough therapy, COVID-19, DNA, News, TSX, Industry, Gene, Apabetalone, Pharmaceutical industry, Medical device, Nature

A further five sites in Brazil and a third Canadian site, in Toronto, Ontario, will also be coming on line soon.

Key Points: 
  • A further five sites in Brazil and a third Canadian site, in Toronto, Ontario, will also be coming on line soon.
  • Through this mechanism, apabetalone has the potential to address both the viral and the more deadly inflammatory aspects of COVID-19.
  • A total of 100 patients are expected to be enrolled over the coming weeks, at multiple sites in Brazil and Canada.
  • A Phase 2b clinical trial is evaluating apabetalone in combination with standard of care for patients hospitalized with COVID-19.

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

Retrieved on: 
Tuesday, January 18, 2022
Biomarker, End organ damage, BET, Patient, Research, SEDAR, News, Intention, Legislation, Inflammation, Risk, Hope, COVID-19, Virus, BD2, Apabetalone, Drug, Cell, Safety, Senior, University of Alberta Hospital, Gene, CEO, Disease, GLOBE, Â, DNA, Standard of care, Breakthrough therapy, Industry, Cardiovascular disease, University, Company, Human body, Conditional sentence, US Foods, Food, TSX, FDA, Omicron, Pharmaceutical industry, Vaccine, Medical device, Nature

The trial will evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19.

Key Points: 
  • The trial will evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19.
  • Today is a landmark moment, as patients suffering from COVID-19 are now receiving apabetalone treatment for the first time, said Donald McCaffrey, President & CEO of Resverlogix.
  • Due to the emergence of the Omicron variant, and the speed with which it has spread, adaptations to the trial have been made to greatly expedite full enrollment.
  • A Phase 2b clinical trial is evaluating apabetalone in combination with standard of care for patients hospitalized with COVID-19.

Resverlogix: The Future of Drug Development, CEO Clip Video

Retrieved on: 
Thursday, December 16, 2021
BET, Bloomberg, CEO, Intact Media Group, Thomson Reuters, COVID-19, Degenerative disease, HIV disease progression rates, Yahoo!, Pharmaceutical industry, Online gambling, Apabetalone

Resverlogix is developing Apabetalone, a first-in-class, epigenetic therapeutic candidate for the potential treatment of COVID-19 and vascular diseases.

Key Points: 
  • Resverlogix is developing Apabetalone, a first-in-class, epigenetic therapeutic candidate for the potential treatment of COVID-19 and vascular diseases.
  • It is a selective BET (bromodomain and extra-terminal) inhibitor targeting one specific domain in contrast to other experimental multi-domain BET inhibitors.
  • CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US.
  • These 90 second video profiles broadcast on national TV and online via 12 financial sites including: Thomson Reuters, Bloomberg, Yahoo!